Publications by authors named "P B Massion"
Purpose: The IL-6 receptor inhibitor tocilizumab reduces mortality and morbidity in severe cases of COVID-19 through its effects on hyperinflammation and was approved as adjuvant therapy. Since tocilizumab changes the levels of inflammatory markers, we aimed to describe these changes in patients treated with tocilizumab, analyse their value in predicting death and bacterial superinfection and determine their influence on mortality rates.
Methods: A retrospective analysis of 76 patients who were treated with tocilizumab for severe COVID-19 in 2020 and 2021 was conducted.
Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands.
Lancet
August 2024
Article Synopsis
- The PRECISe trial aimed to determine if providing critically ill patients on mechanical ventilation with higher protein intake (2.0 g/kg per day) would enhance their quality of life and functional recovery compared to standard protein intake (1.3 g/kg per day).
- This double-blinded, multicentre trial included patients from 10 hospitals across the Netherlands and Belgium, focusing on those expected to need invasive ventilation for at least three days.
- Key aspects of the study included random assignment to either the standard or high-protein group, with blinding of all involved personnel, and tracking the primary outcome through health utility scores at specified intervals (30, 90, and 180 days post-randomization).
Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.
Am J Respir Crit Care Med
September 2024
Article Synopsis
- Lung cancer remains the leading cause of cancer deaths globally, highlighting the need for better understanding of its early development stages to enable timely interventions.
- An international team of scientists identified knowledge gaps in how premalignant lung lesions progress to lung cancer and developed research questions to fill these gaps and guide future investigations.
- Addressing these gaps is crucial for improving screening and early detection methods, which could lead to innovative strategies that effectively reduce lung cancer incidence and enhance patient outcomes.
Background: We recently found that epiplakin 1 (EPPK1) alterations were present in 12% of lung adenocarcinoma (LUAD) cases and were associated with a poor prognosis in early-stage LUAD when combined with other molecular alterations. This study aimed to identify a probable crucial role for EPPK1 in cancer development.
Methods: EPPK1 mRNA and protein expression was analyzed with clinical variables.
Objectives: This study was undertaken to assess CD91 expression on monocytes and changes in monocyte subset distribution during acute tissue damage and bloodstream infection (BSI).
Methods: We investigated blood specimens from healthy individuals, trauma and cardiac surgery patients as a model of tissue damage, and patients with BSI, by flow cytometry using a panel of antibodies comprising CD45, HLA-DR, CD14, CD16 and CD91 for the identification of monocyte subsets.
Results: While infrequent in healthy subjects, CD91low/neg monocyte levels were markedly high in BSI, trauma and after cardiac surgery.